NMDA Receptors: Distribution, Role, and Insights into Neuropsychiatric Disorders.
NMDA channel blockers
NMDA receptors
neuropsychiatric disorders
Journal
Pharmaceuticals (Basel, Switzerland)
ISSN: 1424-8247
Titre abrégé: Pharmaceuticals (Basel)
Pays: Switzerland
ID NLM: 101238453
Informations de publication
Date de publication:
25 Sep 2024
25 Sep 2024
Historique:
received:
21
08
2024
revised:
12
09
2024
accepted:
16
09
2024
medline:
26
10
2024
pubmed:
26
10
2024
entrez:
26
10
2024
Statut:
epublish
Résumé
N-methyl-D-aspartate receptors (NMDARs) are members of the ionotropic glutamate receptor family. These ligand-gated channels are entwined with numerous fundamental neurological functions within the central nervous system (CNS), and numerous neuropsychiatric disorders may arise from their malfunction. The purpose of the present review is to provide a detailed description of NMDARs by addressing their molecular structures, activation mechanisms, and physiological roles in the mammalian brain. In the second part, their role in various neuropsychiatric disorders including stroke, epilepsy, anti-NMDA encephalitis, Alzheimer's and Huntington's diseases, schizophrenia, depression, neuropathic pain, opioid-induced tolerance, and hyperalgesia will be covered. Finally, through a careful exploration of the main non-competitive NMDARs antagonists (channel-blockers). We discuss the strengths and limitations of the various molecular structures developed for diagnostic or therapeutic purposes.
Sections du résumé
BACKGROUND
BACKGROUND
N-methyl-D-aspartate receptors (NMDARs) are members of the ionotropic glutamate receptor family. These ligand-gated channels are entwined with numerous fundamental neurological functions within the central nervous system (CNS), and numerous neuropsychiatric disorders may arise from their malfunction.
METHODS
METHODS
The purpose of the present review is to provide a detailed description of NMDARs by addressing their molecular structures, activation mechanisms, and physiological roles in the mammalian brain. In the second part, their role in various neuropsychiatric disorders including stroke, epilepsy, anti-NMDA encephalitis, Alzheimer's and Huntington's diseases, schizophrenia, depression, neuropathic pain, opioid-induced tolerance, and hyperalgesia will be covered.
RESULTS
RESULTS
Finally, through a careful exploration of the main non-competitive NMDARs antagonists (channel-blockers).
CONCLUSION
CONCLUSIONS
We discuss the strengths and limitations of the various molecular structures developed for diagnostic or therapeutic purposes.
Identifiants
pubmed: 39458906
pii: ph17101265
doi: 10.3390/ph17101265
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng